Abstract
A sensitive high-performance liquid chromatographic (HPLC) assay of the antineoplastic agent VP 16-213 (etoposide) in plasma is described. The system discriminates between the parent compound and possible metabolites, including the aglycone and the cis isomer. After extraction with 1,2-dichloroethane the drugs are chromatographed on a reversed-phase phenyl column with amperometric detection. Quantitative response is linear up to 250 ng/ml for 1 ml human plasma and up to 40.0 μg/ml for 0.1 ml human plasma. The detection limit is ca 2 ng/ml in plasma. Preliminary pharmacokinetic results show that the sensitivity and selectivity of the assay are adequate to establish plasma concentrations over 8-12 half-lives during elimination of the drug.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 89-97 |
| Number of pages | 9 |
| Journal | Journal of Pharmaceutical and Biomedical Analysis |
| Volume | 1 |
| Issue number | 1 |
| DOIs | |
| State | Published - 1983 |
| Externally published | Yes |
Keywords
- anti-tumour agents
- electrochemical chromatographic detection.
- etoposide
- High-performance liquid chromatography
ASJC Scopus subject areas
- Analytical Chemistry
- Pharmaceutical Science